89bio, Inc. financial data

Symbol
ETNB
Location
San Francisco, CA
Fiscal year end
31 December
Latest financial report
10-Q - Q2 2025 - 08 Aug 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1451% % -11%
Debt-to-equity 17% % 35%
Return On Equity -94% % -167%
Return On Assets -81% % -157%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 148,308,250 shares 40%
Common Stock, Shares, Outstanding 148,304,875 shares 41%
Entity Public Float $722,400,000 USD -39%
Common Stock, Value, Issued $148,000 USD 41%
Weighted Average Number of Shares Outstanding, Basic 157,880,203 shares 58%
Weighted Average Number of Shares Outstanding, Diluted 157,880,203 shares 58%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $421,040,000 USD 168%
General and Administrative Expense $44,636,000 USD 31%
Operating Income (Loss) $465,676,000 USD -143%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $448,855,000 USD -163%
Income Tax Expense (Benefit) $1,351,000 USD -67%
Net Income (Loss) Attributable to Parent $450,206,000 USD -158%
Earnings Per Share, Basic -3 USD/shares -88%
Earnings Per Share, Diluted -3 USD/shares -88%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $129,076,000 USD -39%
Marketable Securities, Current $432,088,000 USD 35%
Cash, Cash Equivalents, and Short-term Investments $561,200,000 USD 5.6%
Assets, Current $601,520,000 USD 3.7%
Property, Plant and Equipment, Net $77,000 USD 185%
Operating Lease, Right-of-Use Asset $1,256,000 USD -35%
Other Assets, Noncurrent $632,000 USD 101%
Assets $603,485,000 USD 3.7%
Accounts Payable, Current $14,657,000 USD -16%
Employee-related Liabilities, Current $5,016,000 USD 34%
Accrued Liabilities, Current $24,170,000 USD 30%
Liabilities, Current $39,611,000 USD -4.9%
Operating Lease, Liability, Noncurrent $679,000 USD -54%
Other Liabilities, Noncurrent $5,306,000 USD 41%
Liabilities $81,752,000 USD 22%
Accumulated Other Comprehensive Income (Loss), Net of Tax $122,000 USD
Retained Earnings (Accumulated Deficit) $1,007,290,000 USD -81%
Stockholders' Equity Attributable to Parent $521,733,000 USD 1.3%
Liabilities and Equity $603,485,000 USD 3.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $71,737,000 USD -81%
Net Cash Provided by (Used in) Financing Activities $268,906,000 USD 1179%
Net Cash Provided by (Used in) Investing Activities $7,833,000 USD 90%
Common Stock, Shares Authorized 200,000,000 shares 0%
Common Stock, Shares, Issued 148,304,875 shares 41%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $189,336,000 USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $129,076,000 USD -39%
Interest Paid, Excluding Capitalized Interest, Operating Activities $814,000 USD 20%
Deferred Tax Assets, Valuation Allowance $214,588,000 USD 98%
Deferred Tax Assets, Gross $215,104,000 USD 97%
Operating Lease, Liability $1,817,000 USD -21%
Depreciation $10,000 USD 11%
Payments to Acquire Property, Plant, and Equipment $72,000 USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $449,401,000 USD -157%
Lessee, Operating Lease, Liability, to be Paid $2,094,000 USD -27%
Operating Lease, Liability, Current $784,000 USD 3.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two $937,000 USD 2.2%
Lessee, Operating Lease, Liability, to be Paid, Year One $917,000 USD 18%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $277,000 USD -50%
Lessee, Operating Lease, Liability, to be Paid, Year Three $240,000 USD -74%
Deferred Tax Assets, Operating Loss Carryforwards $89,260,000 USD 42%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $5,300,000 USD
Additional Paid in Capital $1,082,884,000 USD
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance $516,000 USD -28%
Share-based Payment Arrangement, Expense $24,998,000 USD 35%
Interest Expense $5,957,000 USD 67%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%